Search
Povidone K30
go.drugbank.com/drugs/DB14478ApprovedA polyvinyl polymer of variable molecular weight; used as suspending and dispersing agent and vehicle for pharmaceuticals; also used as blood volume expander. See [povidone] for full details.
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or … for the _F508del-CFTR_ gene - this represents approximately 70[A187373]-90%[A187361,A187355] of all CF patients.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTuberculin purified protein derivative
go.drugbank.com/drugs/DB11601ApprovedTuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis.
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalMaralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like [odevixibat]. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseRegdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnTrials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … [L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate.
Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19ALT-P1
go.drugbank.com/drugs/DB18485InvestigationalALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
Tolvaptan
go.drugbank.com/drugs/DB06212ApprovedInvestigationalFDA approved on May 19, 2009.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates